98%
921
2 minutes
20
Uterine contractions, driven by complex electrical activities within the uterine smooth muscle cells, play a critical role in labor and delivery. Various techniques, including EHG and EMMI, have been developed to record and image uterine electrical activities. Both EHG and EMMI use a bandpass filter (fast wave 0.34-1Hz) to preserve uterine contraction activities. However, high-frequency signals are usually weak and are prone to multiple sources of noise and artifacts, significantly impacting the accuracy of contraction detection and subsequent analysis of long- and short-distance signaling in the laboring uterus. Existing methods, such as Zero-Crossing-Rate (ZCR) and Teager-Kaiser Energy Operator (TKEO), employ the transformation of fast wave signals to detect uterine contractions and are still limited by the EHG signal quality. This work proposed a novel method that combines high-frequency (fast wave, 0.34-1Hz) and low-frequency (slow wave, 0.01-0.1Hz) components of uterine electrical signals to generate enhanced EHG signals. Incorporating slow-wave signals offers additional information rather than relying solely on fast wave signals like ZCR and TKEO. Our approach utilizes the stability of slow wave signals to enhance the more noise-prone fast wave signals. This method significantly improves the quality of uterine contraction detection, as evidenced by enhanced signal contrast between contractions and baseline activity. The improved signals enable more accurate detection of contractions and more detailed spatial analysis of uterine contraction propagation. This signal enhancement technique holds great potential for advancing the understanding of long- and short-distance signaling during labor, paving the way for more precise labor management and better maternal-fetal outcomes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12149128 | PMC |
http://dx.doi.org/10.3389/fphys.2025.1568919 | DOI Listing |
Eur Radiol
September 2025
Department of Ultrasound, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China.
Objectives: To evaluate the predictive role of carotid stiffening, quantified using ultrafast pulse wave velocity (ufPWV), for assessing cardiovascular risk in young populations with no or elevated cardiovascular risk factors (CVRFs).
Materials And Methods: This study enrolled 180 young, apparently healthy individuals who underwent ufPWV measurements. They were classified into three groups: the CVRF-free group (n = 60), comprising current non-smokers with untreated blood pressure < 140/90 mmHg, fasting blood glucose (FBG) < 7.
Sleep Adv
July 2025
Division of General Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, United States.
Study Objectives: Circulating non-esterified fatty acids (NEFAs) have been associated with impaired glucose metabolism but their modifiable determinants remain uncertain. We sought to determine the association between objectively-measured sleep disordered breathing (SDB), which is also associated with dysglycemia, and NEFA levels among community-dwelling older adults.
Methods: We analyzed 787 older adults who had total fasting and post-load NEFAs measured in 1996-1997 in the Cardiovascular Health Study and underwent polysomnography between 1995 and 1997 in the Sleep Heart Health Study.
J Obstet Gynaecol Res
September 2025
Fetal-Maternal Medicine, Obstetrics, Gifu Prefectural General Medical Center, Gifu, Gifu, Japan.
Thoracoamniotic shunting is an effective treatment for fetal pleural effusion. Catheter obstruction is a serious and frequently occurring phenomenon that often requires re-shunting; however, accurate diagnosis remains challenging. We present a case in which pulsed-wave Doppler and color flow mapping were used to evaluate fluid flow through a thoracoamniotic shunt catheter.
View Article and Find Full Text PDFLancet
August 2025
Université de Lorraine, Inserm CIC 1433, CHRU, Nancy, France.
Background: Vericiguat is indicated to reduce the risk of cardiovascular death and hospitalisation for heart failure in patients with heart failure and reduced ejection fraction (HFrEF) following a recent worsening event. The aim of the VICTOR trial was to assess the effect of vericiguat in patients with HFrEF without recent heart failure worsening.
Methods: In this double-blind, placebo-controlled, phase 3 trial, conducted at 482 sites across 36 countries, patients aged 18 years or older with HFrEF (left ventricular ejection fraction of ≤40%) without heart failure hospitalisation within 6 months or outpatient intravenous diuretic use within 3 months before randomisation were randomly assigned (1:1) using an intervention randomisation system with interactive response technology to oral vericiguat (target 10 mg dose) or matching placebo.
Lancet
August 2025
Canadian VIGOUR Centre, University of Alberta, Edmonton, AB, Canada.
Background: Following completion of the VICTORIA trial, vericiguat was approved for the treatment of worsening heart failure with reduced ejection fraction (HFrEF) and received a class IIb recommendation in European and North American guidelines. The subsequent VICTOR trial evaluated the use of vericiguat in patients with HFrEF and no recent worsening. We aimed to assess the effect of vericiguat on clinical endpoints through pooled analyses of patient-level data from the VICTORIA and VICTOR trials.
View Article and Find Full Text PDF